PTO/SB/25 (10-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Tragernary Onice, 0.3. Del recommendation of information unless it displays a valid OMB control number.

REMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING **REJECTION OVER A PENDING "REFERENCE" APPLICATION**

Docket Number (Optional) T7770.CON2

	In re Application of: Sanders, et al.	
	Application No.: 10/731,824	
	Filed: 12/08/2003 For: COMPOSITIONS AND METHODS FOR MINIMIZING ADVERSE DRUG EXPERIENCES ASSOCIATED WITH OXYBUTYNIN THERAPY The owner*, <u>Watson Pharmaceuticals, Inc.</u> of <u>100</u> percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number <u>10/731,041</u> filed on <u>12/08/2003</u> as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application are commonly owned. This agreement runs with any patent on the pending reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that: any such patent: granted on the pending reference application in the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed full developed to the true; and further that these statements by any terminal disclaimer filed prior to its grant. Check either box 1 or 2 below, if appropriate. I hereby declare that all stateme	
1		
	Jan W. W. Signature	/ 11/29/2005 Date
		vid W. Osborne
12/05/2005		ed or printed name
06 FC:1814	130.00 QP	(801) 566-6633
i		Telephone Number
	✓ Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
	WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
	*Statement under 37 CFR 3 73(h) is required if terminal disclaimer is signed	by the assigned (numer)

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Form PTO/SB/96 may be used for making this statement. See MPEP § 324.